Drug Channels delivers timely analysis and provocative opinions from Adam J. Fein, Ph.D., the country's foremost expert on pharmaceutical economics and the drug distribution system. Drug Channels reaches an engaged, loyal and growing audience of more than 35,000 subscribers. Learn more...

Tuesday, July 27, 2021

Drug Channels News Roundup, July 2021: Stingy Hospitals, Biosimilars & Part B, Hep C Drug Prices, Costco vs. Part D, and MBA Funny Business

Let’s cut through the summer haze with our refreshing breeze of articles and insights. In this issue:
  • The top 10 stingiest hospitals
  • Medicare Part B's savings from biosimilars 
  • What happened to hepatitis C drug costs and rebates?
  • Costco beats Medicare Part D
Plus, math madness with Duke’s Fuqua business school.

P.S. Please join the more than 12,000 consumers of my daily commentary and links to neat stuff at @DrugChannels on Twitter. You can also find me on LinkedIn, where I have more than 19,000 followers.

Monday, July 26, 2021

Informa Connect’s Hub, SPP and eServices Optimization

Informa Connect’s Hub, SPP and eServices Optimization
Delivered as a Hybrid Event
In-Person: Sep 22-23, New Brunswick, NJ | Virtual: Sep 28-29
www.informaconnect.com/hub-spp/

This important event convenes key stakeholders including manufacturers, specialty pharmacies, hub providers and more for unrivaled collaboration to leverage innovation and optimize access. Be a part of the critical conversation at this timely hybrid meeting to explore proven strategies and cutting-edge approaches to drive an all-encompassing, state-of-the-art hub.

Drug Channels readers will save 10% off the current registration rate when they use code 21HUBDC10*.

Navigate the Evolving Affordability and Regulatory Landscape to Maximize Access
  • Demystify the Evolving Bio/Pharma Affordability Landscape — Key Trends and Dynamics Impacting Access
  • Emerging Trends and Top Risk Areas — Review of Guidance on Copay Assistance, Accumulators and Charitable PAPs
  • NCPDP Standards Update – Specialty Pharmacy and Standards Activity
Uncover Industry Best Practices and Stakeholder Management to Optimize Program Performance
  • Bridge the Gap Between Hubs and Specialty Pharmacies for Improved Patient Experience
  • Optimize Program Design for Cohesive Operational Administration
  • Innovative Model Manufacturer Showcase — Practical Expertise from Industry Experts Enhancing Access, Adherence and Analytics
  • Unpack Hybrid Hubs — How to Make Decisions on Insourced vs. Outsourced Services
  • Discover Patient Support Program Needs for Patients with Rare Diseases
  • Industry Playbook for Focused Investment, Operational Efficiencies, Scorecarding and Metrics
Utilize Data, Analytics and Technology to Enhance Adherence
  • Embrace the Future of Data Driven Patient Support Through Automation and Predictive Analytics
  • Utilize Digital Engagement for End-to-End Patient Support for Specialty Products
  • Achieve Better Patient Outcomes through Tech-Enabled Adherence Programs
  • Leveraging Next-Gen Tech to Enhance Electronic Benefit Verification and Prior Authorizations to Optimize Workflow
  • Improve Patient Engagement through Mobile Messaging and Virtual Assistance
Download the full agenda and save your seat today!

Drug Channels readers will save 10% off the current registration rate when they use code 21HUBDC10*.

*Offer applies to current rates only and may not be combined with other offers, category rates, promotions or applied to an existing registration. Offer not valid on workshop only or academic/non-profit registrations.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Tuesday, July 20, 2021

Specialty Pharmacy’s Explosive 340B Growth

The 340B Drug Pricing Program continues to expand far more quickly than the overall pharmaceutical market—and some channels are benefiting more than others.

As you will see below, mail and specialty pharmacies’ purchases of products that are eligible for 340B discounts have grown by an incredible 56% per year since 2017. That’s about six times faster than the overall mail and specialty market.

Consequently, specialty pharmacies have gained a greater share of the 340B market. Businesses owned by a few multi-billion-dollar, for-profit, publicly traded companies—Cigna, CVS Health, and UnitedHealthcare—are the primary beneficiaries of this astonishing growth.

To help you make sense of the market changes, I have also included a brief video to explain 340B’s growth and the expansion of contract pharmacies. The video is excerpted from my recent Drug Channels Update: 340B Controversies and Outlook video webinar.

Grab some popcorn and enjoy the show!

Monday, July 19, 2021

Informa Connect’s Finance and Accounting for Bioscience Companies – Hybrid Events

Finance and Accounting for Bioscience Companies – Hybrid Events
September 20-21, Boston MA | September 22, Virtual Experience | September 23-24, Burlingame, CA

www.informaconnect.com/financeaccountingeast

www.informaconnect.com/financeaccountingwest

Tailored to the unique nuisances of bioscience companies, these CPE-accredited annual events bring together the brightest financial and accounting minds from the nation’s leading trailblazers.
To best meet the needs of both traveling and stay-at-home audiences, Finance and Accounting for Bioscience Companies East and West will be HYBRID events, combining live and digital experiences that showcase all of the content from the live event, with additional keynotes, panel discussions and meeting scheduling to be fully inclusive to those unable to attend in person.

Drug Channels readers will save 10% off the current rate when they use code 21DRCH10 and register prior to August 13th.* More details are available at the event websites:



Agenda Highlights:

Finance and Accounting for Bioscience Companies – East Coast:
  • Hear directly from leaders at Minovia Therapeutics, Zentalis Phamraceuticals, Takeda, Korro Bio, Tmunity Therapeutics, Generation Bio and more.
  • Attend sessions covering digital transformation, the changing landscape of clinical trials, biotech equity funding models, new product launch planning, forecasting, valuation strategies and more.
  • Earn up to 16.3 CPE credits.
Virtual Experience:
  • Hear strategies to thrive through periods of change from today's most innovative CEOs.
  • Watch the presentation of the Inaugural Life Sciences leaders and Stars Awards, celebrating innovation, achievement, and leadership in the finance community.
  • Attend a Bioscience SPAC Workshop and review classification, valuation and reporting best practices.
  • Don't miss sessions on practical applications of AI, RPA, Machine Learning, IPO and public market update and more.
  • Earn up to 6.5 CPE credits.
Finance and Accounting for Bioscience Companies – West Coast:
  • Hear directly from CFOs as they review the path to the CFO role, lessons on leadership and tackling challenges.
  • Attend sessions covering preparing to go public, market access dynamics, accounting standards updates, accounting for R&D deals and more.
  • Earn up to 15.4 CPE credits.
How to Register:
  • LIVE in Boston with an All Access Pass! Start your week LIVE in Boston on September 20 and 21, and wrap up with a virtual programming on September 22, featuring recordings from BOTH East and West Coast events, as well as live streaming content.
  • LIVE in Burlingame with an All Access Pass! Start your week with the virtual programming on September 22, featuring recordings from BOTH West and East Coast events, and wrap up your week LIVE in Burlingame, CA on September 23 and 24.
  • Go All Virtual! Experience recordings from both meetings, plus live streaming virtual content from the comfort of your home or office on September 22!
Drug Channels readers will save 10% off the current rate when they use code 21DRCH10 and register prior to August 13th.* More details are available at the event websites:

Finance and Accounting for Bioscience Companies – East Coast
Finance and Accounting for Bioscience Companies – West Coast

*Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rate or non-profit rates. Other restrictions may apply.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Friday, July 16, 2021

The Power of Partnerships: Why Pharma Needs to Redefine its Role With IDNs

Today’s guest post comes from MMIT's Dinesh Kabaleeswaran, Director of Advisory Services, and John Griggs, Senior Solution Consultant.

Dinesh and John discuss the expanding role and importance of integrated delivery networks (IDNs) in specialty medication administration and reimbursement.

Dinesh and John also highlight MMIT’s Pulse Analytics solution, which allows pharma manufacturers the ability to monitor drug coverage at the brand and IDN level.

Read on for Dinesh’s and John’s insights.

Wednesday, July 14, 2021

PBMs and Drug Spending in 2020: Data from CVS Health (sort of), Express Scripts, Navitus, and WellDyne (Plus: The Demise of PBM Reporting)

Since 2012, Drug Channels has examined commercial drug spending using the annual trend reports published by the largest PBMs.

This year, we review 2020 data on commercial plan sponsor clients of CVS Health and Express Scripts along with two smaller PBMs—Navitus and WellDyne. As you will see below, plan sponsors experienced another year of single-digit growth in overall pharmacy benefit drug spending.

For specialty drugs, utilization—more people taking more prescriptions—remained the driving force behind this higher spending. Specialty drug costs grew slowly—or even declined.

I’m sad to report that this year’s analysis is skimpier than usual. CVS Health has published only a bare bones summary, while Prime Therapeutics, MedImpact, and other large PBMs have stopped publishing trend reports. I document this disappointing state of affairs below.

Read on as I spread all the the k-poppin' details.

Monday, July 12, 2021

Informa Connect’s PAP: Patient Assistance & Access Programs

Informa Connect’s PAP: Patient Assistance & Access Programs
August 17-19, 2021 | Virtual Event
www.informaconnect.com/pap

Industry’s favorite event is back! Break through affordability barriers with PAP: Patient Assistance & Access Programs taking place August 17-19 in a fully virtual format, and benefit from critical and timely updates addressing the current and anticipated challenges for patient access and assistance professionals.

In a pivotal year for PAPs, join influential stakeholders as they collaborate and uncover industry best practices and stakeholder management to optimize program performance, navigate policy watch-outs and discuss methods to evolve patient assistance through technology and innovation. This event is not to be missed.

Exclusive Offer: View the agenda and register today. Be sure to use your exclusive promo DC4PAP to save 10% off* of your registration.

PAP serves as a three-day conference experience, featuring expert led discussion on the everchanging healthcare and coverage landscape, staying on the pulse of trends in copay exclusions, accumulators and maximizers, solutions to maintain the digital momentum and overcome challenges as we begin to transition to a post COVID-19 world and more. Hear multi-stakeholder perspectives on the most pressing topics and attend tailored content offerings based on your individual needs, including:
  • Executive Outlook: The Intersection on Access and Affordability for Health Policy
  • Build on the ACA Trends to Reduce Coverage Gaps and Disruptions
  • Enforcement Update: Understand DOJ Enforcement Priorities for 2021 and Beyond
  • Three Hot Topic Roundtables
    • Models for Partnership to Advance Program Impact
    • Racial and Income Disparities in Healthcare
    • Compliance and Operational Trends for Nursing Support Programs
  • Three Customizable Learning Streams
    • Technology & Innovation for Streamlined Access
    • Patient Support Collaboration & Operations
    • Legal, Compliance and Policy
  • Industry Disruptors: Stay on the Pulse of Trends in Copay Exclusions, Accumulators and Maximizers
  • Ask the Experts: Setting PAP Industry Standards
  • And more!
PLUS! Introducing a Brand New Digital Platform, ConnectMe:
  • Interactive coffee tables and enhanced networking capabilities
  • Instant message with attendees to continue conversations and spark up one-on-one discussions
  • Suggested connections based on your preferences
  • Sophisticated scheduling tools: Set your availability, book meetings and more
  • Live and on-demand sessions, all available 30-days post-event to review at your leisure
Exclusive Offer: View the agenda and register today. Be sure to use your exclusive promo DC4PAP to save 10% off* of your registration.

Informa Connect will see you there!

*Cannot be combined with other offers, promotions or applied to an existing registration. Other restrictions may apply.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Wednesday, July 07, 2021

Rite Aid’s PBM Strategy: Will Hope Triumph Over Experience?

ICYMI, Rite Aid recently released the financial results for its most recent fiscal quarter, which ended on May 29. Rite Aid’s pharmacy benefit manager (PBM) business, Elixir, continues to flail in an increasingly challenging market.

I’ve long been skeptical of Rite Aid’s PBM strategy. As you will see below, last quarter’s results further validated my skepticism. Synergies with the company’s retail pharmacy business are minimal—and shrinking.

Rite Aid’s management team does seem committed to fixing and then growing the business. But as I see it, the company should either unload Elixir before it loses even more value or join with a larger company that can offer a viable platform for success.

I’m sure many investors wish that Amazon would simply buy Rite Aid and solve their pain.

On the other hand, free advice is often worth what you paid for it. Read on and see what you think the company should do.

Monday, June 28, 2021

Drug Channels News Roundup, June 2021: Amazon's Latest, Patients vs. Accumulators, Generics & Biosimilars, 340B Games, and a Hospital Road trip

Happy 245th birthday, America! As you declare your vaccinated independence, celebrate with these Drug Channels fireworks:
  • Amazon’s teeny step toward pharmacy disruption
  • How patients view copay accumulators
  • My $0.02 on generic and biosimilar trends
  • Some hospitals seem to be gaming their 340B eligibility
Plus, tips on effective hospital marketing.

P.S. Please join the nearly 12,000 consumers of my daily commentary and links to neat stuff at @DrugChannels on Twitter. You can also find me on LinkedIn, where I am approaching 19,000 followers.

Friday, June 25, 2021

Gross-to-Net Bubble Update: Net Prices Drop (Again) at Six Top Drugmakers (rerun)

This week, I’m rerunning some popular posts while I prepare for today’s live video webinar at 12:00 p.m. ET: Drug Channels Update: 340B Controversies and Outlook. More than 2,000 people have already registered for the webinar. Will you be there, too?

Click here to see the original post and comments from April 2021.


Time for Drug Channels' annual update on pricing at six of the largest pharmaceutical manufacturers—Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novartis, and Sanofi. You can find links to each company’s data below.

When rebates and discounts were factored in, brand-name drug prices declined—or grew slowly—in 2020. Consistent with our previous analyses, rebates and discounts reduced the selling prices of brand-name drugs to less than half of their list prices. What’s more, net drug prices have declined for the past four years.

Alas, many pharma industry perma-critics refuse to accept that brand-name drug prices are falling—or that they remain the only part of U.S. healthcare where prices have been declining. That’s why they are drug pricing flat earthers (DPFE.) Consider today’s data deluge as my small contribution to making the world a slightly smarter and more fact-based place.

Thursday, June 24, 2021

The Top 15 U.S. Pharmacies of 2020: Market Shares and Revenues at the Biggest Companies (rerun)

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Update: 340B Controversies and Outlook.

Click here to see the original post and comments from March 2021.


Next week, Drug Channels Institute will release our 2021 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. It’s the 12th edition of our popular and comprehensive examination of the entire drug pricing, reimbursement, and dispensing system. (You can preorder at special discounted prices.)

The exhibit below—one of 211 in our new report—provides a first look at the 15 largest organizations, ranked by total U.S. prescription dispensing revenues for calendar year 2020.

U.S. prescription dispensing revenues reached a record $465 billion in 2020. The largest players all had bigger slices of the revenue pie, due to the growth at specialty pharmacies and multiple transactions that shifted market share among the vertically integrated companies.

For a sneak peek at the complete report, click here to download a free pre-publication draft overview (including the table of contents and a list of exhibits).

Wednesday, June 23, 2021

How GoodRx’s Rapid Growth Creates Conflict between PBMs and Payers (rerun)

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Update: 340B Controversies and Outlook.

Click here to see the original post and comments from March 2021.


Pharmacy pricing and benefit design are fundamentally broken.

For proof, look at GoodRx’s 2020 financial results for its discount card business. The company accounted for an estimated $3.4 billion in U.S. prescription revenues—and earned nearly $500 million in fees from PBMs.

Incredibly, three out of four consumers who used GoodRx already had commercial, Medicare, or Medicaid insurance. This means that someone—the consumer, their employer, and/or the government—paid insurance premiums for a pharmacy benefit managed by a PBM. Yet it was still worthwhile for people to bypass their plan’s out-of-pocket costs and PBM network rates in favor of a different PBM’s rates. As I explain below, such arbitrage creates potent conflicts between PBMs and their plan sponsor clients.

Don’t blame GoodRx for this mess. I give it credit for helping consumers navigate a crazy system that incentivizes people to bypass their own insurance plans. But it’s hard not to dislike a system that enables these games. Read on and let me know what you think.

Tuesday, June 22, 2021

The Top Pharmacy Benefit Managers of 2020: Vertical Integration Drives Consolidation (rerun)

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Update: 340B Controversies and Outlook.

Click here to see the original post and comments from April 2021.


The drug channel is consolidating, both vertically and horizontally.

For evidence, look no further than Drug Channels Institute's estimates of pharmacy benefit manager (PBM) market share, which are shown in the chart below. For 2020, DCI estimates that the three biggest PBMs accounted for more than three-quarters of total equivalent prescription claims.

To help you make sense of recent market changes, I also include a brief video explaining how various transactions and partnerships have concentrated and shifted PBM share among the vertically integrated companies. The video is excerpted from my recent Patients, Payers, and PBMs webinar.

Depending on your role in the drug channel, you may or may not find these data terrifying.

Monday, June 21, 2021

Informa Connect’s IDN & Bio/Pharma Partnering Summit

Informa Connect’s IDN & Bio/Pharma Partnering Summit
August 17-19, 2021 | Virtual Event
www.informaconnect.com/IDN

As part of an evolving healthcare environment, the life science industry is continually challenged to be effective in how it engages health system partners. It is critical that discussions evolve to meet the needs of today and also where healthcare is headed tomorrow.

Visit www.informaconnect.com/IDN for more information. Drug Channels subscribers will save 10% off the current registration rate when they use promo code 21IDNDC10*

To address the challenges and opportunities ahead, join a distinguished group of industry pioneers at Informa Connect’s IDN & Bio/Pharma Partnering Summit—an important event for learning how to best meet the needs of these evolving networks for better patient outcomes.

Diverse Perspectives from Industry Pioneers:
  • Timothy Paine, Vice President, Pharma Strategy & Relations, Fairview Pharmacy Services
  • Kim Coppom, Executive Director, Managed Markets, Relypsa
  • Gerard Taglianetti, Market Access Strategy & Analytics, Pfizer Inc
  • Chip Kurt, Senior Director, Corporate Accounts; Specialty Pharmacy IDNs and GPOs, CSL Behring
  • Richard Stefanacci, DO, MGH, MBA, AGSF, CMD, Medical Director, Population Health, Jefferson College of Population Health
  • Matthew Malchowski, PharmD, BCPS, System Director, Population Health & Ambulatory Care, Ochsner Health Pharmacy
  • Elizabeth Cherry, Program Director, Trade Relations, Vanderbilt Specialty Pharmacy
  • Michael Gannon, PharmD, CSP, Assistant Director, Specialty Pharmacy Services, Ambulatory Pharmacy Services, University of Illinois Health
  • Ryan Haumschild, PharmD., MS, MBA, Director of Pharmacy Services, Emory Healthcare and Winship Cancer Institute
  • Sophia Humphreys, PharmD., MHA, Director, System Pharmacy Clinical Services, Providence St. Joseph Health
  • Ameet Wattamwar, PharmD., Director of Pharmacy, Specialty Pharmacy Program, NYU Langone Health System
  • And more!
High-Impact Topics Driving the Content:
  • State of the Healthcare Industry—Impactful Policy Changes and COVID-19 Implications
  • Best Practices in Working with Payers and PBMs
  • Insights from Leaders in Population Health
  • IDN CEO Fireside Chat: Lessons from Leadership – Priorities and New Directions to Adapt, Align and Advance the Business Forward
  • [Case Study] Innovative Ways to Pay for High Cost Drugs
  • The Next Frontier for IDNs: True Integration of Accountability
  • The Role and Utility of Data and Predictive Analytics to Identify and Service Patient Populations
  • And More!
Visit www.informaconnect.com/IDN for more information. Drug Channels subscribers will save 10% off the current registration rate when they use promo code 21IDNDC10*

*Applies to current rates only and may not be combined with other offers, category rates, promotions or applied to an existing registration. Offer not valid on workshop only or academic/non-profit registrations


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Wednesday, June 16, 2021

EXCLUSIVE: The 340B Program Soared to $38 Billion in 2020—Up 27% vs. 2019

Despite what you may have heard, the 340B Drug Pricing Program continues to thrive.

Discounted purchases under the program reached at least $38 billion in 2020. That figure is an astonishing 27% higher than its 2019 counterpart—and more than quadruple the value of discounted purchases in 2014.

Drug Channels has exclusively obtained the 2020 amount from the Health Resources and Services Administration (HRSA). We received it by filing a Freedom of Information Act (FOIA) request that was just answered yesterday. You can read our FOIA letter below, along with more details on the program's growth.

The 340B program’s size now exceeds the Medicaid program’s outpatient drug sales—and accounts for nearly 20% of the total rebates and discounts that manufacturers provide for brand-name drugs. Alas, many elements of the 340B program—including its controversial contract pharmacy component—lack a comprehensive regulatory infrastructure.

I’ll help you understand what these new figures mean during DCI’s upcoming live video webinar, Drug Channels Update: 340B Controversies and Outlook, on June 25, 2021. Click here to learn more and sign up.

Tuesday, June 15, 2021

Exclusive: 340B Continues Its Unbridled Takeover of Pharmacies and PBMs

Drug Channels Institute’s latest review of contract pharmacies in the 340B Drug Pricing Program reveals that an astonishing 30,000 pharmacy locations—half of the entire U.S. pharmacy industry—now act as contract pharmacies for the hospitals and other healthcare providers that participate in the 340B program.

Over the past 12 months, the number of pharmacies in the program has grown by more than 2,000 locations.

As you will see below, multi-billion-dollar, for-profit, publicly traded pharmacy chains and PBMs—Walgreens, CVS Health, Express Scripts, OptumRx, and Walmart—dominate 340B contract pharmacy relationships with covered entities. 

You can keep your dogecoin and your stonks. The real money lies in the still-booming 340B contract pharmacy business.

I’ll provide more details and crucial context during DCI’s upcoming June 25 live video webinar, Drug Channels Update: 340B Controversies and OutlookClick here to learn more and sign up.

Monday, June 14, 2021

Informa Connect’s 18th Life Sciences Accounting & Reporting Congress

Informa Connect’s 18th Life Sciences Accounting & Reporting Congress
August 10-12, 2021| Virtual Event
www.informaconnect.com/accounting

The Life Sciences Accounting & Reporting Congress Mid-Year Critical Update provides three comprehensive days of CPE accredited content, showcasing insights and expertise from top finance, accounting, and business leaders from across the life sciences sector. And, attendees are invited to local/regional in-person events for valuable networking and peer-to-peer reconnecting.

Visit www.informaconnect.com/accounting-reporting-congress for further details and to register. Drug Channels readers will save 10% off the current rate when they use promo code 21DRCH10 and register prior to July 9th.*

Join us on August 10-12, 2021 as we delve into complex technical accounting hot topics, high-impact industry trends, deal-making, capital markets forecasts, global risks, technology innovations and more. Expert Keynotes, In-Depth Workshops, Small Group Roundtables and Live Q&A Opportunities position attendees to advance career and company success.

Here’s a snapshot of what to expect:
  • CFO Industry Insights Panel on Forces of Change: R&D, Supply Chain, Digital Transformation and Positioning for Future Success
  • Technical Accounting Deep-Dive, with Benchmarking and Financial Reporting Best Practices
  • SEC and Regulatory Corporate Finance Update
  • Governance Considerations, Audit Committee Hot Topics and Board Composition
  • Leadership Panel on Controllership Innovation
  • Wall Street Discussion on Impactful Deals, Investment Trends and Breakthroughs Impacting the Sector
  • Workshops on:
    • IPO and SPAC Roadmaps
    • Product Launch
    • Corporate Tax and Transfer Pricing
    • ESG Metrics and Disclosures
    • Biotech Acceleration Strategies and Gross-to-Net
    • Valuation Models
    • AI and RPA Applied in Finance
Visit www.informaconnect.com/accounting-reporting-congress for further details and to register. Drug Channels readers will save 10% off the current rate when they use promo code 21DRCH10 and register prior to July 9th.*

*Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rate or non-profit rates. Other restrictions may apply.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Friday, June 11, 2021

The Top Five Considerations When Choosing a Patient Solutions Provider

Today’s guest post comes from Jan Nielsen, Division President of AssistRx Patient Solutions.

Jan provides five criteria that manufacturers can use when evaluating the capabilities of a Patient Solutions Provider (PSP), a.k.a. a hub vendor.

To learn more, register for AssistRx's new, four-part webinar series: “Leading the Market in a Rapidly Changing Patient Solutions Landscape.”

Read on for Jan’s insights.

Tuesday, June 08, 2021

Pharmacist Job Market in 2020: Hospital Employment Up, Retail Salaries Down

The Bureau of Labor Statistics (BLS) has recently released its employment and salary data for 2020. That means it’s time to update Drug Channels Institute’s (DCI) annual analysis of pharmacist salaries and employment.

We have found that the share of pharmacists who work at hospitals reached a new high. What’s more, average base salaries for retail pharmacists have dropped, while salaries have risen for pharmacists employed by hospitals, physician offices, and other non-retail settings. 

A word of caution: These data were collected during the peak of last year’s pandemic shutdowns. I suspect that 2020 will turn out to have been a much more challenging year for retail-employed pharmacists.

The 340B Drug pricing Program is a crucial topic for pharmacists. For a deep dive, join me for DCI’s upcoming live video webinar, Drug Channels Update: 340B Controversies and Outlook , on June 25, 2021, from 12:00 p.m. to 1:30 p.m. ET. CLICK HERE TO LEARN MORE AND SIGN UP.


Monday, June 07, 2021

National Association of Specialty Pharmacy (NASP) 2021 Annual Meeting & Expo

National Association of Specialty Pharmacy (NASP) 2021 Annual Meeting & Expo
September 27-30, 2021 | Marriott Marquis, Washington, D.C.
www.nasp.com/annualmeeting
Early Bird Registration Discount Ends June 30.

The National Association of Specialty Pharmacy (NASP) returns to Washington, D.C. on September 27-30 for the National Association of Specialty Pharmacy (NASP) 2021 Annual Meeting & Expo. The 2021 event will welcome attendees to a new conference venue—the beautiful and modern Marriott Marquis, located in the heart of downtown Washington, D.C.

Register today for this premier industry event! Discounted registration rates are available through June 30.

The NASP 2021 Annual Meeting & Expo will challenge and inspire attendees, sponsors, and exhibitors to Reimagine What’s Possible. We will focus on looking at our world differently—reimagining our teams, families, patients, business, the patient journey and ourselves. We will appreciate who we are at our best and understand the power of our presence. Join us to engage in interactive learning, share best practices, explore potential partnerships and synergies, and foster connectivity in a personalized, intimate setting.

The conference agenda is jam packed and offers something for everyone, whether you are new to the industry or a seasoned expert. Conference highlights include:
  • Up to 15 hours of unique CE accredited educational sessions and panel discussions, organized into four dynamic tracks to help you focus on what is most important to you
  • Encore presentations of the most popular sessions
  • THREE KEYNOTE PRESENTATIONS
    • Justin Patton, executive coach, will lead the conference in challenging attendees to Reimagine What’s Possible.
    • Monica Pearson, distinguished journalist and humanitarian, and the first woman and first minority to anchor the daily evening news in Atlanta, Georgia.
    • Montel Williams, an Emmy Award winner, decorated former naval officer, inspirational speaker, author, entrepreneur, multiple sclerosis patient, and advocate for patients worldwide.
  • Four pre-conference workshops: the CSP Exam Preparation Course, Legal Day, Technology Day and Hospital/Health Systems Workshop (additional fee required for workshops)
  • Dynamic Exhibit Hall featuring exhibitors representing stakeholders from across the specialty pharmacy industry
  • The ever-popular Women in Specialty Pharmacy Luncheon, featuring motivational keynote speaker Amelia Rose Earhart
  • CE satellite symposia
  • Poster presentations and author discussions
  • NASP Annual Meeting Awards presentations—including three new awards—the Caregiver of the Year award, the Pharmacist of the Year award, and the Pharmacy Technician of the Year award
  • The NASP Ron Bookman Scholarship Awards
  • Direct interaction with industry thought leaders and experts
  • Ample networking opportunities
  • Odyssey Dinner Cruise, an upscale dining and network experience along the Potomac River (additional fee required)
The safety of our guests is NASP’s top priority. We continue to work with federal, state, and local health officials to strictly adhere to current rules and requirements and do everything possible to protect the health and safety of all attendees.

Register today for this important industry event! Discounted registration rates are available through June 30.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Friday, June 04, 2021

Technology and Human Care Combine to Support the Medication Access Journey

Today’s guest post comes from Nathan Mott, President of CoverMyMeds.

Nathan discusses how technology can augment human expertise to help people access, afford, and adhere to their medications.

To learn more, download CoverMyMeds’ new solutions overview: Technology Helps Drive Medication Access, Adherence and Affordability.

Read on for Nathan’s insights.

Wednesday, June 02, 2021

How CVS Health Drives McKesson’s Distribution Financials

McKesson recently released the annual report for its 2021 fiscal year, which ended on March 31.

The report provides fresh insights about the company’s business with CVS Health, its largest customer. As you will see, CVS purchased $50 billion in pharmaceuticals from McKesson—more than triple the figure from 10 years ago.

The report also reveals that CVS Health paid McKesson in about 24 days, providing the wholesaler with an often-overlooked cash flow benefit. In fact, McKesson’s overall business had a negative cash conversion cycle. That’s essential for a low margin distribution business.

Below, I delve into the financials behind these two elements of the McKesson-CVS relationship. You’ll understand why CVS is McKesson’s worst best friend.

Join me for DCI’s upcoming live video webinar, Drug Channels Update: 340B Controversies and Outlook , on June 25, 2021, from 12:00 p.m. to 1:30 p.m. ET. CLICK HERE TO LEARN MORE AND SIGN UP.

Tuesday, June 01, 2021

NEW: Drug Channels Update: 340B Controversies and Outlook (live video webinar)

Dr. Adam J. Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels, invites you to join him for his latest live video webinar:

Friday, June 25, 2021 (12:00 p.m. to 1:30 p.m. ET)

This event is part of The Drug Channels 2021 Quarterly Video Webinar Series. Anyone who registered for the entire series will receive an email with a link to access the June event.

WHAT YOU WILL LEARN

Dr. Fein will help you and your team stay on top of the current trends and market developments. During the June 25 event, Dr. Fein will focus on the latest developments regarding contract pharmacies in the 340B Drug Pricing Program, including:
  • Evolution of the 340B program
  • Our 2021 analysis of the 340B contract pharmacy market
  • The flow of funds in a 340B contract pharmacy network
  • How 340B impacts payers, plan sponsors, and PBMs
  • How 340B disrupts manufacturer-PBM rebates
  • Current program administration controversies
  • The latest manufacturer actions and covered entity responses
  • How to make sense of ongoing litigation
  • Policy options and actions
  • Possible resolutions to the contract pharmacy conflict
  • And more!
PLUS: During the webinar, Dr. Fein will give participants an opportunity to unmute themselves and ask live questions. The webinar will be 90 minutes to accommodate audience questions.

The 340B Drug Pricing Program remains highly controversial. As always, Dr. Fein will clearly distinguish his opinions and interpretations from the objective facts and data.

Read on for full details on pricing and registration. You can also watch a brief video invitation.

Tuesday, May 25, 2021

Drug Channels News Roundup, May 2021: 340B & PBMs, Benefit Design Problems, Overworked Pharmacists, Hospitals Keep Grabbing Physicians, and New Patent Games

Summer unofficially begins this weekend! Let’s turn up the heat with these sizzling news bites straight from the Drug Channels grill:
  • Cardinal Health delivers fresh evidence of PBM profiteering from 340B contract pharmacies
  • Pharma critics dare to acknowledge that benefit designs actually matter
  • Pharmacists at retail chains are really stressed out
  • Hospitals’ takeover of the physician market continues
Plus, more troubling patent news for owners of intellectual property.

P.S. Join the nearly 11,800 followers of my daily links to neat stuff at @DrugChannels on Twitter. You can also follow me on LinkedIn.

Friday, May 21, 2021

Six Trends to Watch in the New Healthcare Economy

Today’s guest post comes from Karen Eckert, Senior Manager of Commercial Support for Clinical Effectiveness at Wolters Kluwer, Health. She also serves as co-chair of Maintenance and Control at the NCPDP.

Karen examines trends in drug development, pricing, and healthcare. She explains how coordinated intelligence can help businesses improve effectiveness in the new healthcare economy.

To learn more, download Six trends and tactics to thrive in the new healthcare economy, a free white paper from Wolters Kluwer.

Read on for Karen’s insights.

Tuesday, May 18, 2021

The Specialty Pharmacy Accreditation Boom Slows: DCI’s Exclusive Update on the U.S. Market

It’s time for Drug Channels Institute’s annual update of the number of U.S. specialty pharmacies. Fortunately, I had outstanding research assistance. (See photo at right.)

As you will note below, the specialty pharmacy industry remains quite diverse—despite the concentration of dispensing revenues within a small number of companies.

Our proprietary analyses have identified more than 1,200 locations that have achieved specialty pharmacy accreditation from one of the two major independent accreditation organizations. 

Overall accreditation growth appears to be slowing. However, pharmacy locations owned by healthcare providers—hospitals, health systems, physician practices, and providers’ group purchasing organizations—now account for nearly 40% of all accredited specialty pharmacy locations.

Read on for a bite of our arithmomania.

Monday, May 17, 2021

LexisNexis Webinar: Using SDoH Data to Supercharge Outreach and Engagement

Lexis Nexis Webinar: Using SDoH Data to Supercharge Outreach and Engagement
June 24, 2021 | 1:00 pm ET | Virtual Event

The shift to real-world evidence and real-world data has driven a significant transformation in healthcare. While EMR, medical, and pharmacy claims data is important and has traditionally been the main source of information for life science companies, that data doesn’t give a complete picture of the patient. Studies show that medical determinants are only accountable for 20% of healthcare outcomes, whereas social determinants of health account for as much as 50%.

Join experts from LexisNexis® Risk Solutions to:
  • Learn how your organization can accelerate its growth by applying data and analytics
  • Gain new insight into additional opportunities for R&D
  • Support outreach efforts to targeted patient populations
A wealth of data can be extracted from vast sources of public records and proprietary data sources, but more data isn’t always better. Combining the right, clinically validated data points can transform your business and the outcomes you are working to improve.

Register for the June 24 LexisNexis webinar today.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Friday, May 14, 2021

Prescribing and Policy Trends Affecting Medication Access in 2021

Today’s guest post comes from Kyle Grimslid, Clinical Solutions Director at CoverMyMeds.

Kyle discusses the prescribing trends and policies that emerged in 2020. He highlights the growing importance of pharmacists and the role of technology in improving patient access, affordability, and adherence.

Read more in CoveryMyMeds’ 2021 Medication Access Report: Legislative and Regulatory Edition. (free download)

Read on for Kyle’s insights.

Wednesday, May 12, 2021

How Cigna’s Growing Pharmacy Platform Expands Its Channel Power

Last week, Cigna released its earnings for the first quarter of 2021. Links below.

I was struck by how quickly Cigna’s Express Scripts PBM business has increased revenues and prescriptions from its retail pharmacy network. Our second chart below highlights this growth.

The businesses in Cigna's Evernorth segment—especially Express Scripts, Ascent Health Services, and InsideRx—are already providing rebate negotiation, network management, and/or a sourcing platform for Prime Therapeutics, Kroger, Humana, GoodRx, and Amazon. 

I expect Cigna’s influence over the drug channel to expand further as other businesses step onto this burgeoning platform.

Monday, May 10, 2021

Informa Connect’s Formulary, Reimbursement and Access Summit 2021

Informa Connect’s Formulary, Reimbursement and Access Summit 2021
July 27-29, 2021 | Virtual Event
www.informaconnect.com/formulary-access/

Formulary, Reimbursement and Access Summit provides a forum for industry to convene, benchmark and gain strategies to explore new and impending access and managed market challenges within the value-based landscape while providing insights on valuable patient services and support programs, healthcare market coverage and strategies to improve overall access and reimbursements of commercialized drugs.

Drug Channels readers are eligible for an exclusive savings of 10% off* the current rate by using promo code 21FRADC10, be sure to reserve your seat today!

Gain critical insights from a distinguished speaking faculty including:
  • Michael Thompson, President & CEO, National Alliance of Healthcare Purchaser Coalitions
  • D.R. McCale III, MDY, RMC, Director, Market Access and Reimbursement, Akcea Therapeutics
  • Shannon D. Ashmon, MBA, Senior Manager, Access & Reimbursement, Oncology Business Unit, Eisai, Inc.
  • Peter Avalos, National Reimbursement Director, Daiichi Sankyo, Inc.
  • Jeff Blake, Senior Vice President, Payer Relations, Hemophilia Alliance
  • Shawn Gremminger, Health Policy Director, Pacific Business Group on Health
  • And many more!
Transform Access Strategies with Compelling Discussions Around
  • Formulary Insights – Advancements in Design and Management
  • The Future of Rebate Reform – Explore Current and Pending Legislation
  • Assess the Landscape for Prior Authorization and Reimbursement Support - Reexamining the Roles of the Manufacturer and the Pharmacy
  • Value-Based Contracting Frameworks and Considerations
  • Digital Therapies and Telehealth – Define their Role in the Evolving Healthcare Landscape
  • And so much more!
Plus! Choose between 3 Interactive Workshops on Day 2!

Drug Channels readers are eligible for an exclusive savings of 10% off* the current rate by using promo code 21FRADC10, be sure to reserve your seat today!

*Offer may not be combined with other offers, category rates, promotions or applied to an existing registration. Offer not valid academic/non-profit registrations.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Friday, May 07, 2021

Predicting Enrollment Changes in the COVID Era

Today’s guest post comes from Jill Brown Kettler, Executive Editor at AIS Health, a division of MMIT.

Jill discusses MMIT's proprietary data on how the COVID-19 pandemic affected enrollment in commercial plans, Medicaid, and health insurance exchanges. 

To learn more about 2020 enrollment changes and the 2021 outlook, register for MMIT’s free webinar on May 18 at 1:00 pm ET: Meet the Expert: Predicting Enrollment Changes in the Covid Era.

Read on for Jill’s insights.

Tuesday, May 04, 2021

DCI’s Top 15 Specialty Pharmacies of 2020: PBMs Expand Amid the Shakeout—While Walgreens’ Outlook Dims

In Drug Channels Institute's list of the top 15 pharmacies of 2020, we show that many of the largest U.S. market participants are now central-fill mail and specialty pharmacies operated by PBMs and insurers.

To complement that broader ranking, we present below our exclusive list of the top 15 pharmacies based on specialty drug dispensing revenues. You will see that PBMs and insurers have increased their dominance over specialty drug channels. Many of the largest independent companies have been acquired.

As we look ahead, CVS Health and Cigna’s Express Scripts seem best positioned for further growth. However, AllianceRx Walgreens Prime—the joint venture between Walgreens Boots Alliance and Prime Therapeutics—faces significant market share loss.

Read on for all the details.

Monday, May 03, 2021

Informa Connect’s Annual Commercial Contracts & Chargebacks Congress

Informa Connect’s Annual Commercial Contracts & Chargebacks Congress
June 23-25, 2021 | Virtual Event
informaconnect.com/contracts-chargebacks

Informa Connect’s 17th Annual Commercial Contracts & Chargebacks Congress, taking place virtually June 23-25, offers crucial updates on policy changes and contracting best practices to increase efficiency, reduce revenue leakage, and streamline chargeback excellence. 

This annual event has become a must-attend for pricing and contracting professionals in the life sciences industry with seasoned leaders and forward-thinking strategies on display. Join industry stakeholders, including manufacturers, wholesalers, GPOs and more, for a robust three-day event offering extended content and actionable strategies in key interest areas in the ever-evolving contracting landscape.

Drug Channels readers are eligible for an exclusive savings of 10% off* the standard rate by using promo code 21CCCDC10, so download the complete conference agenda and reserve your seat today!

Featured Faculty Driving the Conversation:
  • John Shakow, Partner, King and Spalding
  • Susanne Somerville, Chief Executive Officer, Chronicled
  • Edward McAdam, Director, Government Pricing, Contracting Operations & Analytics, Indivior
  • Mike Domanico, Vice President Finance, Revenue, Sandoz (Novartis)
  • Beth Stevens, Associate Director, Contracts & Pricing, TOLMAR Pharmaceuticals
  • Sherice Koonce, Director of Contracts, Hikma Pharmaceuticals
  • Fred Fieder, Director, Contract Administration, McKesson
  • Susan Lowe, Senior Vice President, Supply Chain Operations, FFF Enterprises
  • Brian Green, Head of Contract Operations, UCB Pharma
  • Felicia Manning, Associate Director, Market Access, Pricing & Reimbursement, Theravance BioPharma US
  • And many more!
Hight Impact Topics Transforming the Market Include:
  • Policy Update on 340B and Pharmacy Channel Evolution
  • Contract Management Reimagined — Operational Excellence Strategies for Increased Process Efficiencies and Reduced Revenue Leakage
  • Strategic Contracting Industry Insights Panel — The Confluence of Data, Financial Analytics and Value
  • Revolutionize and Automate Transactions using Blockchain
  • GPO Panel featuring Vizient, Premier Inc. and more!
  • Contract Administration Industry Insights Panel — Process Improvement in Contract Administration and Management — Streamlining Chargeback Operations, GPO Rosters and Channel Operations
Drug Channels readers are eligible for an exclusive savings of 10% off* the standard rate by using promo code 21CCCDC10, so download the complete conference agenda and reserve your seat today!

*Expires 6/25/20210; applies to standard rate only and may not be combined or applied to existing registrations; other restrictions may apply.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Friday, April 30, 2021

How Non-Commercial Pharmacies Accelerate Patients Into Prescription Programs

Today’s guest post comes from Natalie Tyler, Director of Pharmacy Operations & Strategy at ConnectiveRx.

Natalie discusses how non-commercial pharmacies boost patient access and adherence to specialty therapies. They also help physicians deliver better care.

On May 24 at 1:00 pm ET, ConnectiveRx will host an online panel discussion on non-commercial pharmacy services with experts from ConnectiveRx and AstraZeneca. Click here to register here for this free event. Email inquiries@ConnectiveRx.com with any questions.

Read on for Natalie’s insights.

Tuesday, April 27, 2021

Drug Channels News Roundup, April 2021: Cigna’s $500 Gift, 340B & Specialty Pharmacy, GoodRx Deep Dive, and U.S. Drug Pricing Policy

While we all roll up our sleeves for a full reopening, let’s spring into this month’s selection of noteworthy news:
  • Thoughts on Cigna’s payments to patients for non-medical switching
  • 340B’s explosive specialty pharmacy growth
  • An excellent analysis of GoodRx
Plus, my $0.02 on U.S. drug pricing policy.

P.S. Join the more than 11,600 followers of my daily links to neat stuff at @DrugChannels on Twitter. Recent posts have covered biosimilars, pharmacist workloads, formularies, pricing, PSAOs, Part D spending, copay accumulators, H.R.3, and more. You can also join my more than 17,000 followers on LinkedIn.

Monday, April 26, 2021

Making Health Policy Work for Patients: How Platform Solutions Enable More Affordable Drugs (Kalderos)

At Kalderos, we use data-driven solutions to deliver unifying technologies to solve problems facing the U.S. healthcare system, so that everyone can focus on the health of patients. We created the world’s first Drug Discount Management platform. This platform uses sophisticated models and machine learning to identify and then resolve noncompliance in drug discount programs.

On April 20, we released Making Health Policy Work for Patients: How Platform Solutions Enable More Affordable Drugs (free download), our first-ever annual report. 

Our 2021 annual report shares our perspective on challenges with discount and rebate programs in the drug channel and reports on our rapid growth as a health tech platform. It explores:
  • How systemic inefficiencies mean patients pay more for drugs
  • Why past drug price interventions have failed the patients who need them most
  • The tech-enabled, data-driven way to fix drug distribution and put patients first
The report also includes never-before-published insights leveraged from Kalderos’ proprietary data, drawing on our tech-enabled solutions for Discount Monitoring in the 340B Drug Pricing Program:
  • Our estimated total amount of duplicate discounts between 340B and Medicaid in 2019 based on our platform gathering more than four years of good-faith inquiry data from covered entities
  • Key metrics describing Kalderos’ growing network of relationships with stakeholder partners and increasing impact in 340B
The 2021 annual report also sets a vision for our company’s future as we continue our trajectory of rapid scaling, with a product roadmap that includes an expansion into data-driven, transparency-minded platform solutions for other drug discount programs.

Download the full report from Kalderos.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Friday, April 23, 2021

The Value of Patient-Centricity in Tech-Enabled Medication Access Solutions

Today’s guest post comes from Erica Conroy, Vice President of Specialty at CoverMyMeds.

Erica discusses four technology areas that the healthcare network can embrace to increase speed to therapy, affordability, and adherence.

To learn more about CoverMyMeds' specialty medication access solutions, download their new whitepaper: Helping Patients Access Specialty Therapies: Autoimmune Conditions. (Free download)

Read on for Erica’s insights.

Tuesday, April 20, 2021

Express Scripts 2020 Update: Utilization Drove Drug Spending Growth—While Maximizers Gained Further Traction

Cigna’s Evernorth business has recently released its 2020 Drug Trend Report. The results, which reflect the Express Scripts PBM business, are presented as a series of animated webpages. As you can see, Chief Innovation Officer Dr. Glen Stettin is newly cartooned.

For commercial plan sponsors, pharmacy benefit spending grew by 4.0%. However:
  • More than three-quarters of this spending growth was due to the growth in utilization—the number of people being treated and the number of prescriptions being dispensed.
  • The net, post-rebate costs of drugs rose by only 0.9%.
Details and comments about some therapeutic classes below. 

SaveonSP, the secretive copay maximizer partner of Express Scripts, apparently again drove big specialty savings for some plans in 2020. I wonder how many plan sponsors have probed the profits and operations of this business?

Monday, April 19, 2021

Informa Connect’s Compliance Congress for Specialty Products

Informa Connect’s Compliance Congress for Specialty Products
June 22-24, 2021 | Virtual Event
www.informaconnect.com/specialty-compliance/

Exclusive Offer: Use promo code SPECIALTY10 to save 10% off* your registration fee.

Up your compliance game at this important event serving the unique sector of Specialty Products, the 7th annual Virtual Compliance Congress for Specialty Products. Join the compliance community for dynamic discussions on the top risk areas for specialty pharmaceutical companies, including speaker programs, patient support programs, charitable donations, specialty pharmacy relationships, patient advocacy group interactions, mergers and acquisitions, medical affairs activities, drug pricing, transparency and more!

The Compliance Congress for Specialty Products serves as a three-day conference experience, featuring top experts ready to lead robust discussions on the current and changing environment, industry best practices, hot-button topics and more, including:
  • Enforcement Trends & Prosecutor Perspectives
  • COVID-19 Impacts & Aftermath
  • Crisis Management & Business Continuity
  • Patient Interactions & Support Programs
  • Virtual/Digital Engagement & Monitoring
  • Transparency & Aggregate Spend
  • Drug Pricing Legislation & Transparency
  • Compliance Training & Culture Development
  • Speaker Programs
  • And more!
Outstanding Virtual Capabilities:
  • Interactive presentations and panels
  • Live Q&A and polling
  • Live and on-demand sessions, all available 30-days post-event to review at your leisure
  • 1-1 meeting opportunities and peer-to-peer engagement
  • Sophisticated and seamless scheduling tools
PLUS: Advance Your Career with CLE, CPE & CCB accredited content!

Exclusive Offer – View the full agenda and register today. Use promo code SPECIALTY10 to save 10% off* your registration fee.

Informa Connect will see you there!

*Cannot be combined with other offers, promotions or applied to an existing registration. Other restrictions may apply.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees. To find out how you can reach the Drug Channels audience, please contact Paula Fein (paula@DrugChannels.net).


Friday, April 16, 2021

Choosing the Optimal Pharmacy Model for Retail and Specialty-Lite Products

Today’s guest post comes from Jeff Spafford, President and CEO at AssistRx.

Jeff discusses aspects of our drug pricing system that lead to decreased new and refill prescription volume, higher out-of-pocket costs for patients, and therapy abandonment.

To learn more about AssistRx’s technology solutions register for their Optimizing Program Performance: An Innovative Approach for Retail and Specialty Products webinar series.

Read on for Jeff’s insights.

Wednesday, April 14, 2021

Gross-to-Net Bubble Update: Net Prices Drop (Again) at Six Top Drugmakers

Time for Drug Channels' annual update on pricing at six of the largest pharmaceutical manufacturers—Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novartis, and Sanofi. You can find links to each company’s data below.

When rebates and discounts were factored in, brand-name drug prices declined—or grew slowly—in 2020. Consistent with our previous analyses, rebates and discounts reduced the selling prices of brand-name drugs to less than half of their list prices. What’s more, net drug prices have declined for the past four years.

Alas, many pharma industry perma-critics refuse to accept that brand-name drug prices are falling—or that they remain the only part of U.S. healthcare where prices have been declining. That’s why they are drug pricing flat earthers (DPFE.) Consider today’s data deluge as my small contribution to making the world a slightly smarter and more fact-based place.

Monday, April 12, 2021

Informa Connect’s Patient Support Services Congress

Informa Connect’s Patient Support Services Congress
June 15-17, 2021 | VIRTUAL EVENT (All-Digital Format)
www.informaconnect.com/patient-support-services/

Patient Support Services is a dialogue driven meeting that arms the industry with trends and next-generation approaches to patient services for optimal performance. Showcasing innovative discussions on access strategy, patient interactions, case management, compliance practices and more, this two-and-a-half-day event navigates a myriad and mounting level of compliance hurdles while strengthening and innovating patient-oriented programs.

Drug Channels readers save 10% off the current registration rate with promo code 21PSSDC10.* Register today.

In-Depth Discussions and Actionable Takeaways on Critical Topics:
  • Keep a Pulse on Emerging Trends for 2021 — Update on Drug Pricing Pressures, Patient Assistance Programs, Evolving Copay Card Legislation and Formulary Transformations
  • Enforcement Update — Oversight and High Priority Risk Areas for Patient Services
  • Industry Playbook for Risk Mitigation — Leading Frameworks to Enhance your Compliance Strategy
  • Enhance the Stakeholder Experience — Operational Insights on Specialty Patient Connectivity
  • Capture and Optimize Patient Data to Create an Integrated Experience
Customizable Experience with Two Tailored Tracks:
  • Legal and Compliance
  • Innovation and Operations
Featured Faculty Driving the Conversation:
  • Esther Langer, Head of US Patient Services, Trade and Distribution, Apellis Pharmaceuticals
  • Paul J. Koob, Assistant U.S. Attorney, U.S. Attorney’s Office for the Eastern District of Pennsylvania
  • Jolie Apicella, Assistant U.S. Attorney, Chief, Health Care Fraud, U.S. Attorney’s Office, Eastern District of New York
  • Rahul Khara, Pharm.D., Vice President, Legal and Chief Compliance Officer, Acceleron Pharma Inc.
  • Amy Wilson, Head, U.S. Compliance, Morphosys
  • Karen Tenenbaum, Vice President, Assistant General Counsel, Head of Legal, Salix
  • Liam Moy, Senior Director, Patient Services, Neurology, Alexion Pharmaceuticals
  • Katherine Chaurette, Vice President Healthcare Law and Compliance, Blueprint Medicines
  • Dave MacLeod, Head of Patient Services and Specialty Pharmacy Operations, Amylyx Pharmaceuticals
  • Robert Britting, Director, Patient Services and Strategic Solutions, Teva Pharmaceuticals
  • And so many more!
Comprehensive Content and Dynamic Features Include:
  • 3 days of live content from industry thought-leaders
  • 10+ on-demand sessions, tailored to both access and compliance
  • Over 4 hours of live speaker Q&A
  • AI-powered virtual networking with colleagues and counterparts
  • Private meeting and chat rooms
  • Access to live and on-demand content for 30 days post-event
Drug Channels readers save 10% off the current registration rate with promo code 21PSSDC10. Register today.

*Offer applies to standard rates only and may not be combined with other offers, category rates, promotions or applied to an existing registration. Offer not valid on workshop only or academic/non-profit registrations.


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Friday, April 09, 2021

A Framework to Optimize Patient Access And Drive Value in the Care Continuum

Today’s guest post comes from William Dupere, Practice Lead and Vice President of Market Access at TrialCard.

Bill discusses specific barriers to access, affordability, and adherence in the specialty pharmacy patient journey. To learn more about TrialCard’s patient access solutions, please visit their Resources page. You can also contact them at sales@trialcard.com.

Read on for Bill’s insights.

Tuesday, April 06, 2021

The Top Pharmacy Benefit Managers of 2020: Vertical Integration Drives Consolidation

The drug channel is consolidating, both vertically and horizontally.

For evidence, look no further than Drug Channels Institute's estimates of pharmacy benefit manager (PBM) market share, which are shown in the chart below. For 2020, DCI estimates that the three biggest PBMs accounted for more than three-quarters of total equivalent prescription claims.

To help you make sense of recent market changes, I also include a brief video explaining how various transactions and partnerships have concentrated and shifted PBM share among the vertically integrated companies. The video is excerpted from my recent Patients, Payers, and PBMs webinar.

Depending on your role in the drug channel, you may or may not find these data terrifying.

Thursday, April 01, 2021

Streamlining the Specialty Therapy Prescribing and Enrollment Experience

Today’s guest post comes from Megan Marchal, CoverMyMeds Specialty Pharmacy’s pharmacist in charge.

Megan discusses a recent enhancement to AMP: Access for More Patients™ (AMP), a tech-enabled hub and patient access service from CoverMyMeds and RxCrossroads by McKesson. Read more about technology and patient access in CoverMyMeds’ 2021 Medication Access Report.

Read on for Megan’s insights.

Wednesday, March 31, 2021

Drug Channels News Roundup, March 2021: Sanofi’s Gross-to-Net Bubble, Express Scripts Rebates, Health Insurance Hustle, and Vertical Integration Illustrated

Spring has finally reached our worldwide headquarters here in lovely downtown Philadelphia. (See photo at right.) Before your allergies kick in, please inhale this month’s selection of noteworthy news stories:
  • Sanofi: Drug prices drop, but patient costs increase
  • A new rebate disclosure from Express Scripts
  • The health insurance hustle
Plus, a 2021 update to my infamous chart of the seven biggest vertically integrated organizations that combine insurers, PBMs, specialty pharmacies, and healthcare providers.

P.S. Join the more than 11,400 followers of my daily links to neat stuff at @DrugChannels on Twitter. You can also join my more than 16,000 followers on LinkedIn.

Monday, March 29, 2021

Informa Connect's Medicaid and Government Pricing Congress

Medicaid and Government Pricing Congress
June 8-11, 2021 | Virtual Event
www/informaconnect.com/medicaid-congress

Register today using the exclusive Drug Channels discount code 21MDGP10 to receive 10% off!

The Medicaid and Government Pricing Congress, an important event dedicated to critical policy updates and approaches to effectively contract, report and comply with state and federal healthcare programs, returns June 8-11, 2021.

Hear from GP Experts on MDRP trends and strategies and the impacts from the change to a new administration. The 2021 event has a content-rich agenda, providing the most up-to-date content and topics based on the ever-changing political and regulatory environment, fresh perspectives from small to big pharma and more interaction in the virtual environment.

Up-To-Date Content
We’ve got all of the key legal and consultant perspectives on topics like 340B (including contract pharmacy arrangements), State Price Transparency, CMS current and final rules, Most Favored Nations, and more!

Fresh Perspectives
Along with many of the well-respected experts typically on the program from companies like Gilead, Sandoz, CMS, AstraZeneca, Pfizer and Regeneron, we’ve added new speakers form Amgen, Jazz Pharmaceuticals, Novartis and more!

More Interaction
In addition to our select Panel Discussions and the insightful Fireside Chat with Outside Counsel, we’ve added interactive working groups led by expert Facilitators from manufacturers, law firms, and consulting groups to discuss everything from Product Launch, Divestiture and Acquisition Challenges to State Dispute Resolution and Collaboration during the pandemic, to State Price Transparency and Reporting.

PLUS our world-class content including topics like the in-depth GP 101 Bootcamp, operational effectiveness sessions, updates from OIG and more! Register today using the exclusive Drug Channels discount code 21MDGP10 to receive 10% off!


The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Friday, March 26, 2021

What I told Congress about the 340B Program (rerun)

This week, I’m rerunning some popular posts while I prepare for today's live video webinar: Drug Channels Quarterly Update: Patients, Payers, and PBMs.

Click here to see the original post and comments from November 2020.


ICYMI, House Energy and Commerce Committee Republican Leader Greg Walden (R-OR) and Senate Health, Education, Labor and Pensions (HELP) Committee Chairman Lamar Alexander (R-TN) recently asked for input on how to improve the 340B Drug Pricing Program. Comments were due last Friday (October 30).

Your friendly neighborhood blogger submitted an 11-page letter, which you can read below. I shared my $0.02 on the overall market, explained channel distortions from 340B contract pharmacies, and offered some policy recommendations.


For your reference, I also include links to published comments from the American Hospital Association and the Pharmaceutical Research and Manufacturers of America.

The new Congress has an ambitious agenda. Let’s hope modernizing 340B gets on the do list.